ARKG is trading 3.3% lower today as investors reassess valuations in innovative healthcare following a surge in M&A activity and strategic deals.
- The recent Eli Lilly–AtaiBeckley acquisition and a broader consolidation wave in biotech and digital health have triggered profit-taking and rotation within high-beta healthcare.
- While strategic deals have boosted select individual names, the broader thematic ETF is under pressure from shifting investor sentiment and valuation adjustments.
- The decline comes despite broadly mixed equity markets, highlighting a specific rotation out of genomic innovation names following the recent deal surge.